News

PipelineReview.com14h

AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

NORTH CHICAGO, IL, USA I August 21, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 ...
PipelineReview.com14h

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

(Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and ...
PipelineReview.com14h

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other ...
PipelineReview.com14h

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

REYKJAVIK, Iceland and LONDON, UK I August 21, 2025 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of ...
PipelineReview.com14h

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform

SANTA MONICA, CA & PHILADELPHIA, PA, USA I August 21, 2025 I Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive ...